Cardiocast

FDA: Benefits still outweigh risks from paclitaxel-coated devices for PAD

Publish date: January 24, 2019

 

This week, the FDA weighs in on concerning reports about paclitaxel-coated stents, and it approves a device to treat patent ductus arteriosus in infants weighing as little as 2 pounds. Also, a treat-to-target approach for CVD risk factors decreased atherosclerosis in rheumatoid arthritis patients, and ezetimibe was effective for primary prevention in elderly patients.

Subscribe to Cardiocast wherever you get your podcasts.
Amazon Alexa
Apple Podcasts

Recommended Reading

‘Payoff will be great’ if we can conquer childhood obesity, expert says
MDedge Internal Medicine
Gender, racial, socioeconomic differences found in obesity-depression link
MDedge Internal Medicine
Postprandial glucose responses to identical meals vary from person to person
MDedge Internal Medicine
Too much, too little sleep linked to atherosclerosis
MDedge Internal Medicine
HDL-P subfractions may be prognostic in heart failure
MDedge Internal Medicine
Impact of carbs vs. fats on CVD risk becoming better understood
MDedge Internal Medicine
Novel agent cut LDL in statin-intolerant patients
MDedge Internal Medicine
Treat-to-target approach for CVD risk factors decreased atherosclerosis in RA patients
MDedge Internal Medicine
Sleep: Too much, too little both tied to atherosclerosis
MDedge Internal Medicine
Ezetimibe found effective for primary prevention in elderly
MDedge Internal Medicine